URACIL DERIVATIVES AS TRPA1 INHIBITORS

The present disclosure provides certain uracil derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes...

Full description

Saved in:
Bibliographic Details
Main Authors BINDER, Florian Paul Christian, WILLWACHER, Jens, FLECK, Martin Thomas
Format Patent
LanguageEnglish
Published 17.10.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The present disclosure provides certain uracil derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
AbstractList The present disclosure provides certain uracil derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
Author FLECK, Martin Thomas
WILLWACHER, Jens
BINDER, Florian Paul Christian
Author_xml – fullname: BINDER, Florian Paul Christian
– fullname: WILLWACHER, Jens
– fullname: FLECK, Martin Thomas
BookMark eNrjYmDJy89L5WRQCw1ydPb0UXBxDfIMcwzxDHMNVnAMVggJCnA0VPD08_B08gzxDwrmYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXxjqFGBkZGRqaWpsbmjpbGxKkCADtfJjI
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID AU2022259537A9
GroupedDBID EVB
ID FETCH-epo_espacenet_AU2022259537A93
IEDL.DBID EVB
IngestDate Fri Oct 25 05:36:31 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_AU2022259537A93
Notes Application Number: AU20220259537
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241017&DB=EPODOC&CC=AU&NR=2022259537A9
ParticipantIDs epo_espacenet_AU2022259537A9
PublicationCentury 2000
PublicationDate 20241017
PublicationDateYYYYMMDD 2024-10-17
PublicationDate_xml – month: 10
  year: 2024
  text: 20241017
  day: 17
PublicationDecade 2020
PublicationYear 2024
RelatedCompanies BOEHRINGER INGELHEIM INTERNATIONAL GMBH
RelatedCompanies_xml – name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Score 3.5765216
Snippet The present disclosure provides certain uracil derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title URACIL DERIVATIVES AS TRPA1 INHIBITORS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241017&DB=EPODOC&locale=&CC=AU&NR=2022259537A9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_mFPVNpzJ1SkHpW7EfWWMfhrRpSyuuLf1ib6NZOxBkDlfx3_daOt3T3kIOLsmRy90vubsAPOoGVdWiINISXTeJGLoiFRXhEpU5IcaScLVNCpsGupeR19l41oOPbS5MWyf0py2OiBq1QH2v2_N6_X-JZbexlZsn_o5dny9uOrHFDh2jOcIdJtrWxIlCO2QiY4gkxSBuaLhzjbFGTeMADtGRpk0AmJNbTV7KeteouGdwFCG_VX0OvWo1gBO2_XttAMfT7skbm532bS5AzGKT-W-CjeArN1M_dxLBTIQ0jkxF8APPt_w0jJNLeHCdlHkSDjj_W9_czHZnp11BH5F_NQRhIatlhQgAJaYTQyaFVpUFl2lJS16o5fM1jPZxutlPvoXTRmLNQazQEfTrr-_qDi1sze9bwfwCwN953g
link.rule.ids 230,309,783,888,25578,76884
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ZS8NAEB5qFeubVsWjakDJWzDHNmkeiuQk0Vzkom8h26QgSC024t93ElrtU9-WXZjdHeb6dndmAZ5kVRHFsiTcAkM3jqiywJU1oZzCU0LUBaFilxTmB7KTkdfZeNaDj20uTFcn9KcrjogaNUd9bzp7vfo_xDK7t5XrZ_qOXZ8vdjo12Q06RneEEsaa-tSKQjM0WMNAJMkGcTuGkquOJUVTD-AQg-xJW2nfyvU2L2W161TsUziKkN6yOYNevRzCwNj-vTaEY39z5Y3Njfatz4HNYs1wPcZE8JVrqZtbCaMlTBpHmsC4gePqbhrGyQU82lZqOBxOWPztr9Cy3dVJl9BH5F9fATPnxapGBIAck4nKk1Kqq5LySqVUtBSryTWM9lG62T_8AAMn9b3Cc4O3WzhpudcaZUEZQb_5-q7v0Ns29L5j0i-fgXzO
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=URACIL+DERIVATIVES+AS+TRPA1+INHIBITORS&rft.inventor=BINDER%2C+Florian+Paul+Christian&rft.inventor=WILLWACHER%2C+Jens&rft.inventor=FLECK%2C+Martin+Thomas&rft.date=2024-10-17&rft.externalDBID=A9&rft.externalDocID=AU2022259537A9